Q2 2025 Vitrolife AB Earnings Call Transcript
Key Points
- Vitrolife AB (VTRLY) achieved a 9% organic growth in its Consumables business, outperforming the market and gaining share from competitors.
- The Americas region delivered a 5% organic growth in local currency despite challenging market conditions due to the IVF executive order.
- Vitrolife AB (VTRLY) became the lead investor in AutoIVF, advancing its strategy to create an end-to-end IVF platform.
- The EMEA region showed strong performance with a 17% growth in Consumables, excluding discontinued business, indicating significant market share gains.
- The company reported a strong balance sheet with an equity ratio of 78.8% and a net debt to EBITDA ratio of 0.8x.
- Sales decreased by 7% in SEK, heavily impacted by an 8% negative currency effect.
- Gross margin decreased to 58%, affected by currency fluctuations and increased supply chain costs.
- EBITDA decreased to SEK243 million, with a margin of 27.8%, impacted by currency and increased US sales and marketing investments.
- Operating cash flow dropped to SEK151 million, and earnings per share fell to SEK0.74.
- The APAC region experienced flat organic growth, with market weakness in China and delayed capital purchases affecting performance.
Welcome to Vitrolife Q2 2025 earnings call. (Operator Instructions)
Now, I will hand the conference over to CEO Bronwyn Brophy and CFO Helena Wennerström. Please go ahead.
' -
Good morning, everyone. I would like to welcome you to the Vitrolife Group Q2 2025 earnings report. As mentioned, my name is Bronwyn Brophy O´Connor. I'm the CEO of the Vitrolife Group and I'm joined by Helena Wennerström, our acting CFO. I would like to now move you to the slide entitled Q2 2025 Highlights.
I would like to start by highlighting three key achievements during the quarter. The first highlight was the performance of our Consumables business, delivering 9% organic growth in local currencies, excluding discontinued business. This growth rate is significantly above current market growth rates in the quarter, and there is no doubt that we are taking share from the competition across the portfolio.
The second point I would like to highlight is the performance of our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
